Alpha Tau Medical (DRTS)
(Delayed Data from NSDQ)
$2.83 USD
+0.16 (5.99%)
Updated May 17, 2024 04:00 PM ET
After-Market: $2.74 -0.09 (-3.18%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DRTS 2.83 +0.16(5.99%)
Will DRTS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for DRTS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DRTS
Is Alpha Tau Medical (DRTS) Stock Outpacing Its Medical Peers This Year?
Best Momentum Stocks to Buy for January 8th
DRTS: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for January 8th
Down -20.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Alpha Tau Medical Ltd. (DRTS)
What's in Store for Patterson Companies (PDCO) in Q4 Earnings?
Other News for DRTS
Innovative Alpha DaRT Cancer Treatment Promises Broad Usability and Efficacy, Merits Buy Rating
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
Alpha Tau announces Alpha DaRT treatment of first patient with liver cancer
Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow
Alpha Tau presents preclinical data at 2024 ESTRO